Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381639 | 1.00 | NPSR1 (0.49) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL10560406 | 0.98 | NPSR1 (0.46) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL10560424 | 0.98 | NPSR1 (0.46) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL8997538 | 0.90 | SMN1; SMN2 (0.38) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL8984934 | 0.90 | SMN1; SMN2 (0.38) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL10561685 | 0.83 | LMNA (0.45) | NPSR1EPHX1KDM4EALDH1A1HTT | |
| SCHEMBL7972229 | 0.83 | LMNA (0.45) | NPSR1EPHX1KDM4EALDH1A1HTT | |
| SCHEMBL3069802 | 0.82 | EPHX1 (0.52) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL3069805 | 0.82 | EPHX1 (0.52) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 | |
| SCHEMBL21647247 | 0.81 | NPC1 (0.53) | NPSR1EPHX1EPHX2NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | NPSR1 1778/4885EPHX1 1287/4885EPHX2 2490/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | NPSR1 1276/4885EPHX1 948/4885EPHX2 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.